Evaluation of Dyslipidemia, Lipid Ratios, and Atherogenic Index As Cardiovascular Risk Factors Among Semi-urban Dwellers in Nigeria
Overview
Affiliations
Background And Objectives: The increasing frequency of cardiovascular disease (CVD) rests on the presence of major cardiovascular risk factors including dyslipidemia. This dyslipidemia is also a target for the prevention and treatment of many cardiovascular diseases. Hence, identification of individuals at risk of CVD is needed for early identification and prevention. The study was carried out to evaluate dyslipidemia using the lipid ratios and indices instead of just the conventional lipid profile.
Methodology: It was a cross-sectional study with 699 participants recruited from semi-urban communities in Nigeria. Anthropometric indices, blood pressure, and fasting lipid profiles were determined. Abnormalities in lipid indices and lipid ratios with atherogenic index were also determined. SPSS software version 17.0 were used for analysis, P< 0.05 was considered statistically significant.
Results: There were 699 participants with a mean age of 64.45 ± 15.53 years. Elevated total cholesterol, high low-density lipoprotein-cholesterol, elevated triglyceride, and low high-density lipoprotein were seen in 5.3%, 19.3%, 4.4%, and 76.3% of the participants, respectively. The Castelli's risk index-I (CRI-I) predicted the highest prevalence of predisposition to cardiovascular risk (47.8%) with females being at significantly higher risk (55.2% vs. 29.3%, P< 0.001). Atherogenic coefficient, CRI-II, CHOLIndex, atherogenic index of plasma (AIP) predicted a cardiovascular risk prevalence of 22.5%, 15.9%, 11.2%, and 11.0%, respectively, with no significant difference in between the sexes.
Conclusions: Serum lipid ratios and AIP may be used in addition to lipid parameters in clinical practice to assess cardiovascular risks even when lipid profiles are apparently normal. AIP was more gender specific amidst the lipid ratios.
Bamidele Adelowo A, Lemos Ferreira N, Gupta A, Khan Z Cureus. 2025; 16(12):e75888.
PMID: 39822425 PMC: 11737606. DOI: 10.7759/cureus.75888.
Bucurica S, Nancoff A, Dutu M, Mititelu M, Gaman L, Ionita-Radu F Biomedicines. 2024; 12(8).
PMID: 39200151 PMC: 11351771. DOI: 10.3390/biomedicines12081686.
Lhilali I, Zouine N, Godderis L, El Midaoui A, El Jaafari S, Filali-Zegzouti Y Eur J Investig Health Psychol Educ. 2024; 14(8):2337-2357.
PMID: 39194949 PMC: 11354124. DOI: 10.3390/ejihpe14080155.
Sasmana I, Wihandani D, Sadeva I, Halim W, Agustini P, Samala L Turk J Med Sci. 2024; 54(2):401-410.
PMID: 39050394 PMC: 11265884. DOI: 10.55730/1300-0144.5805.
Dienda Y, Onkin J, Nkodila Natuhoyila A, Lubenga Y, Swambulu T, Mbuyamba-Kabangu J J Diabetes Res. 2024; 2024:4078281.
PMID: 39035683 PMC: 11260213. DOI: 10.1155/2024/4078281.